

# Mahesh Patel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4850914/publications.pdf>

Version: 2024-02-01

9  
papers

113  
citations

1478505

6  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

95  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical safety evaluation of levonadifloxacin, a novel anti-methicillin-resistant <i>Staphylococcus aureus</i> benzoquinolizine fluoroquinolone by intravenous and oral administration. <i>Journal of Applied Toxicology</i> , 2022, 42, 1354-1370.	2.8	2
2	Assessment of the <i>in vitro</i> cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic. <i>Xenobiotica</i> , 2021, 51, 251-261.	1.1	5
3	Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 54, 128432.	2.2	8
4	Assessment of <i>in vitro</i> inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes. <i>Xenobiotica</i> , 2020, 50, 1149-1157.	1.1	4
5	<i>In Vivo</i> Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against <i>Staphylococcus aureus</i> in a Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	7
6	&lt;p&gt;Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 4351-4365.	4.3	44
7	<i>In vitro</i> bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant <i>Staphylococcus aureus</i> biofilms. <i>Journal of Medical Microbiology</i> , 2019, 68, 1129-1136.	1.8	15
8	WCK 4873 (Nafithromycin): Assessment of <i>In Vitro</i> Human CYP Inhibitory Potential of a Novel Lactone-Ketolide. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	8
9	Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of <i>Streptococcus pneumoniae</i> and <i>Streptococcus pyogenes</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 1130-1133.	3.0	20